Thompson Davis & Co’s GenMark Diagnostics, Inc GNMK Stock Holding History

Thompson Davis & Co’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-500	Closed	-$7K	–	1295
2014 Q4	$7K	Hold	500	–	–	0.01%	870
2014 Q3	$4K	Sell	500 -250	-33%	-$2.69K	0.01%	962
2014 Q2	$10K	Sell	750 -750	-50%	-$7.83K	0.01%	490
2014 Q1	$15K	Sell	1,500 -2,000	-57%	-$24.9K	0.02%	426
2013 Q4	$47K	Buy	+3,500	New	+$42.5K	0.07%	246

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thompson Davis & Co's GNMK Position: Q1 2015 in Review

Thompson Davis & Co sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2015, closing a stake of 500 shares — an estimated $7K sold.

Thompson Davis & Co first reported a position in GNMK in Q4 2013 and held it in 5 quarters. The position peaked at $47K in Q4 2013. 80 funds tracked by Wall St. Rank hold GNMK as of Q1 2015.

Thompson Davis & Co reported no remaining GenMark Diagnostics, Inc position as of Q1 2015 after selling out during the quarter.
Thompson Davis & Co sold 500 GenMark Diagnostics, Inc shares in Q1 2015, an estimated $7K.
Thompson Davis & Co first reported a position in GenMark Diagnostics, Inc in Q4 2013 and held it in 5 quarters.
Thompson Davis & Co's GenMark Diagnostics, Inc position peaked at $47K in Q4 2013.
80 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2015, filed 28 Apr 2015.